Abstract
Introduction
The markets segments for therapeutics for hematological malignancies are
numerous and complicated. The historical general conception that relatively
low prevalence diseases, has been insufficient in size to allow companies to
quickly regain their investment is clearly out of date. In this perspective
enhanced development is expected. Among the emerging therapeutic strategies,
passive and active immunotherapies have clearly continued to be leading
strategies. Small molecule apoptotic inducers and kinase inhibitors are as
well in the forefront.
About this report
In this unique report, Global Pipeline Review & Analysis of Hematological
Malignancies, BioSeeker reports on the hematological cancer pipeline by:
- Investigator - Includes 212 investigators and partners
- Drug - Includes 237 “active” drugs
- Sub-indication - Includes 11 sub-indications
- Developmental stage - Includes 8 developmental stages
- Compound type - Includes 21 different compounds types
- Targeted therapy strategy - Includes 5 different targeted therapy
strategies
- Target - Includes 97 different protein targets
- Signaling pathway - Includes 18 different signaling pathways
All of above “factors” are cross referenced against each other,
generating highly valuable insights in 40 figures and 53 tables. Read more
below about each “factor” included in this cutting edge analysis.
| 
View Cart
